Skip to main content
Uncategorized

IRB to develop an innovation project on bone metastasis

By 5 de March de 2014November 18th, 2020No Comments
< Back to news
Gomis's laboratory will develop the project "New markers for bone metastases". Photo: G. Battista, IRB.
 05.03.2014

IRB to develop an innovation project on bone metastasis

Today the agency for business competitiveness of the Generalitat de Catalunya, ACCIÓ, has announced the award of more than 90,000 euros of funding for the technology transfer project called "New markers for bone metastases". Over the next two years, ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB), head of the Growth control and cancer metastasis lab, will develop the project.


VALTEC technology valorisation funding is a new line of resources to motivate technology and research centres to conduct projects and activities of technological value and to offer them tools to compete in the market. The projects have to be in a precompetitive stage and the funding allows them to reduce the uncertainties about the commercial viability of the technology in question.

Gomis seeks to identify molecular targets that will allow the future development of a diagnostic test on the capacity of primary tumours to metastasize to the bone. His group studies the way in which growth factors, signalling pathways and gene expression programmes control normal proliferation of cells and the metastasis of cancer cells. The team is identifying the genes that selectively act as mediators in breast cancer metastasis to specific organs such as bones.

At the end of 2010, Gomis set up the spin-off enterprise Inbiomotion, specialized in the development of markers to predict bone metastases on the basis of primary tumour analysis. In 2012, Inbiomotion received a 2-million euro investment form the capital risk company Ysios Capital.

For further information [+]